ArticleHuman vaccines & immunotherapeutics2026
Implementing single-dose HPV vaccination in Canada.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization and the National Advisory Committee on Immunization now recommend a single-dose HPV vaccine schedule for most immunocompetent adolescents. As Canadian jurisdictions transition to a single-dose schedule, we apply a social and behavioral science lens and draw on lessons from previous vaccine schedule changes and international experience to identify potential challenges and opportunities associated with this transition. Key implementation considerations include maintaining public confidence through transparent communication about the rationale for the schedule change, ensuring healthcare providers, immunizers, and parents are adequately prepared to support the transition, and promoting equitable access through robust catch-up programs and targeted outreach initiatives. Attention to these factors will be critical to supporting successful implementation of single-dose HPV vaccination programs in Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.